Comparing two forms of letrozole plus ribociclib for advanced breast cancer
Part of Cancer, Skin clinical trials.
This study tests a new version of the hormone therapy letrozole (Letrozole SIE) compared to the standard letrozole (Femara®), both given together with a targeted therapy called ribociclib. It is for postmenopausal women with HR-positive, HER2-negative breast cancer that has spread to other parts of the body and has not yet been treated for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman who is postmenopausal (no period for 12+ months or ovaries removed).
- Your breast cancer is hormone receptor-positive (HR+) and HER2-negative, and it has spread to other parts of the body (metastatic) or is locally advanced and cannot be removed by surgery.
- You have not had any previous cancer treatment for this advanced or metastatic breast cancer. You may have had chemotherapy before the cancer spread (as part of initial treatment).
- You have a good overall health status (ECOG score 0-2) and your organs (like liver, kidneys, bone marrow) are working well enough.
- You have not had serious heart problems, uncontrolled high blood pressure, or a history of lung disease (pneumonitis or interstitial lung disease).
- You are not taking certain medications or supplements that could interfere with the study drugs (like strong CYP3A inducers or inhibitors, grapefruit, or hormonal medications).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (BGB-43395) combined with letrozole against the usual CDK4/6 inhibitor plus letrozole. It is for people with advanced or metastatic HR-positive, HER2-negative breast cancer who have not yet had treatment for advanced disease.
This trial tests a new approach: starting with a targeted pill (ribociclib) plus hormone therapy (an aromatase inhibitor), instead of immediate chemotherapy, for women with a specific type of breast cancer (ER low-positive, HER2-negative) that is growing quickly. If eligible, you would not have received any prior treatment for your advanced cancer.
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
This trial studies whether adding ribociclib to standard hormone (endocrine) therapy lowers the risk of breast cancer coming back in early-stage, hormone-receptor–positive cancer. It mainly looks at safety and how well the treatment controls cancer after surgery and (sometimes) prior hormone treatment.
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
This trial tests a combination of two drugs, camizestrant and ribociclib, for people with a certain type of advanced breast cancer (HR+/HER2-). It is for those whose cancer has grown or spread despite previous hormone therapy. The goal is to see if this new combination can help control the cancer.
Hear when a new Advanced/Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.